Read a trial result with its limits.

A checklist for reading a weight-loss result.

• Check who took part.

  STEP 1 enrolled adults without diabetes who had obesity, or who had excess weight along with a related health condition.

  A trial is a study that compares treatments. A dummy treatment, also called a placebo, lets researchers make that comparison.

• Keep the extra care in the picture.

  Both groups also received help with food choices and physical activity.

  Novo Nordisk, the medicine’s maker, funded the trial.

  Semaglutide group

  Dummy injection group

  After 68 weeks in STEP 1, the semaglutide group had lost an average of 14.9% of starting weight; the dummy injection group’s average loss was 2.4%.

  An average describes the group. It does not predict your result.

• Match the result to the product studied.

  This result came from a semaglutide injection trial, not a trial of pharmacy-made copies.

  Medicine that a doctor or pharmacist prepares for an order is called a compound.

  As of September 26, 2026, the US Food and Drug Administration warned against claiming that a compound has been proven to match an approved medicine’s results.

• Ask what happened after stopping.

  The STEP 1 follow-up found that participants had put back on roughly two-thirds of their lost weight a year after treatment stopped.

  Ask how follow-up, future costs and a possible stopping plan fit your care. The trial does not decide how long your own treatment will last.